Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.61 |
| ▸ | CES1 | P23141 | 5/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934144 | 0.83 | CES2 (0.58) | CES2CES1BCHEHPGDALB | |
| SCHEMBL3930146 | 0.81 | KAT6A (0.43) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL6604138 | 0.77 | CES2 (0.57) | CES2CES1BCHEHPGDALB | |
| SCHEMBL3184940 | 0.76 | CES2 (1.00) | CES2CES1BCHEHPGDALB | |
| SCHEMBL3440833 | 0.76 | CES2 (0.74) | CES2CES1BCHEHPGDALB | |
| SCHEMBL3563696 | 0.76 | CES2 (0.55) | CES2CES1BCHEHPGDALB | |
| SCHEMBL8517295 | 0.75 | ALDH1A1 (0.46) | CES2CES1HPGDALDH1A1ALOX15 | |
| SCHEMBL5613020 | 0.75 | CES2 (0.65) | CES2CES1BCHEHPGDALB | |
| SCHEMBL8383833 | 0.74 | CES2 (0.48) | CES2CES1BCHEHPGDALB | |
| SCHEMBL9419922 | 0.74 | CES2 (0.53) | CES2CES1BCHEHPGDALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043656-B1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIV GREENWICH (GB) | 2014-02-12 | — | — | EP | disclosed |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2013-01-03 | — | — | US | disclosed |
| US-8268823-B2 | Medical use of triazine derivatives | UNIVERSITY OF GREENWICH (GB) | 2012-09-18 | — | — | US | disclosed |
| US-20090291954-A1 | Medical Use of Triazine Derivatives | UNIVERSITY OF GREENWICH (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-2043656-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | University of Greenwich (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008007149-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2008-01-17 | — | — | WO | disclosed |
| CN-1030911-C | Dibenzoylalkylcyanohydrazines | ROHM & HAAS (US) | 1996-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291954-A1 | Medical Use of Triazine Derivatives | KCNH1, KCNJ1, KCNN1 | CES2 518/4885CES1 1304/4885BCHE 4028/4885 |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | KCNJ1, KCNH1, KCNJ11 | CES2 977/4885CES1 1494/4885BCHE 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.